Monday, December 23, 2024

Innovative Patient Engagement Technology for Infusion Providers with WeInfuse Partnerships

WeInfuse, a leading software platform for infusion therapy and medication delivery, is renewing its commitment to deliver a comprehensive and best-in-class patient engagement solution for its infusion provider clients by integrating with Formstack and Twilio.

Given the chronic nature of autoimmune disorders, the complexity of therapy, and the frequency of treatment, infusion providers need to stay engaged with their patients throughout their treatment journey. To aid providers in maintaining the necessary engagement that is vital to treatment success, WeInfuse is rebuilding its patient engagement feature set from the ground up, powered by Twilio and Formstack.

WeInfuse will leverage Twilio’s secure Application Programming Interface (API) to power its appointment reminder and patient messaging features. The integration with Formstack will supply WeInfuse’s infusion provider clients with customizable forms for intake, feedback surveys, patient consents, medication order forms, and more.

Also Read : Perficient reaches definitive agreement to acquire SMEDIX, INC.

“We are very excited to be partnering with Formstack,” said WeInfuse CEO & Co-Founder Bryan Johnson. “Our team at WeInfuse has worked tirelessly to bring innovative technology to infusion providers, and the Formstack partnership and integration will continue our commitment to advancing technology for our valued clients.”

Over time, Formstack will be deeply integrated into the WeInfuse workflow to allow a streamlined and simplified communication and documentation process between infusion operators and their patients.

“Our mission is to find new and better ways to help people simplify their processes and make their patients’ lives easier so they can focus on their treatments,” said Formstack CEO Chris Byers. “Formstack is honored to be partnering with the WeInfuse team to continue innovating their workflows and delivering greater value to patients.”

SOURCE : PRNewswire

Subscribe Now

    Hot Topics